351370-67-7

Basic information

• Product Name: 2-(1-BENZYL-PYRROLIDIN-3-YL)-PROPAN-2-OL
• Synonyms: 2-(1-BENZYL-PYRROLIDIN-3-YL)-PROPAN-2-OL
• CAS NO: 351370-67-7
• Molecular Formula: C₁₄H₂₁NO
• Molecular Weight: 219.32
• Mol File: 351370-67-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-(1-BENZYL-PYRROLIDIN-3-YL)-PROPAN-2-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(1-BENZYL-PYRROLIDIN-3-YL)-PROPAN-2-OL(351370-67-7)
• EPA Substance Registry System: 2-(1-BENZYL-PYRROLIDIN-3-YL)-PROPAN-2-OL(351370-67-7)

Safety Data

• Hazardous Substances Data: 351370-67-7(Hazardous Substances Data)

Usage

Structure

A derivative of propan-2-ol with a pyrrolidine ring and a benzyl group attached to the 1-position

Potential pharmaceutical applications

Structurally related to certain drugs and has been investigated for its effects on the central nervous system

Unique chemical properties

Contributed by the benzyl group and the pyrrolidine ring

Biological activities

Potential for various medical conditions

Further research and development

May reveal its potential as a drug candidate or lead compound for the treatment of various medical conditions

Upstream product

• 17012-21-4 1-benzylpyrrolidine-3-carboxylic acid methyl ester 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 351369-41-0 2-(pyrrolidin-3-yl)propan-2-ol 

Relevant articles and documents

AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS

Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R1, R2, R3, R4, R5, R6, R7, X1, X2, X3, X4, X5, X6, X7, X8, and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R2, R3, R4, R5, R6, R7, R8, R9, X1, X2, and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R2, R3, R4, R5, R6, R7, R9, X1, X2, and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.